Zenda Technologies - Overview DETECT -> DIAGNOSE-> TREAT Lawrence Catchpole - CEO [email_address]

Who we are Lawrence Catchpole - President and CEO Mitch Gilstrap - COO Michelle LaPlaca , PhD – Co-Inventor David Wright, MD – Co-Inventor

Lawrence Catchpole - President and CEO

Mitch Gilstrap - COO

Michelle LaPlaca , PhD – Co-Inventor

David Wright, MD – Co-Inventor

Effective Screening Tool for Alzheimer's Disease US Population with AD - 5M today - 16M by 2050 Current test is a paper based test given by a trained administrator that requires 60 minutes in a quiet room 95% of patients already have moderate to severe AD at initial diagnosis – TOO LATE IMTech – Immersive neuropsychological screening device Test time drastically reduced to 10 minutes More consistent and accurate results than today’s best practice Part of your annual physical – a mental test to complement the physical tests 2006 - 40 person clinical study a success 400 person clinical study will be completed this May

US Population with AD - 5M today - 16M by 2050

Current test is a paper based test given by a trained administrator that requires 60 minutes in a quiet room

95% of patients already have moderate to severe AD at initial diagnosis – TOO LATE

IMTech – Immersive neuropsychological screening device

Test time drastically reduced to 10 minutes

More consistent and accurate results than today’s best practice

Part of your annual physical – a mental test to complement the physical tests

2006 - 40 person clinical study a success

400 person clinical study will be completed this May

Business Opportunity Business model based on recurring test revenue Available market = 100 million tests/year (Over 50) Insurance reimbursement is $66 per test Gross margin expected – 90% Currently raising our A round Other addressable markets (Concussion) High Contact Sports for young people Military – traumatic brain injury

Business model based on recurring test revenue

Available market = 100 million tests/year (Over 50)

Insurance reimbursement is $66 per test

Gross margin expected – 90%

Currently raising our A round

Other addressable markets (Concussion)

High Contact Sports for young people

Military – traumatic brain injury